Pyrimidinyl tyrosine kinase inhibitors
The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
1. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
6. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
8. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
10. A method for decreasing the enzymatic activity of Bruton's tyrosine kinase comprising contacting Bruton's tyrosine kinase with an effective amount of a compound of claim 1 or a composition thereof.
11. A method for treating a disorder in a human subject in need of treatment for dysregulation of BCR signaling, the method comprising:
administering to the subject an effective amount of a compound of claim 1 or a composition thereof, the compound being a Bruton's tyrosine kinase inhibitor;
wherein the disorder is responsive to B-cell depletion.
12. A method for treating a disorder selected from the group consisting of autoimmune disorders, inflammatory disorders, and cancers affiliated with B-cells, the method comprising:
administering to a human subject an effective amount of a compound of claim 1 or a composition thereof;
wherein the disorder is responsive to B-cell depletion.
13. The method of claim 12 , wherein the disorder is rheumatoid arthritis.
14. The method of claim 12 , wherein the disorder is systemic lupus erythematosus.
15. The method of claim 12 , wherein the disorder is atopic dermatitis.
16. The method of claim 12 , wherein the disorder is leukemia or lymphoma.